BIGBEAR
PHARMACEUTICALS
Encorafenib is an oral, highly selective BRAF V600 mutant kinase inhibitor, often used in combination with MEK inhibitors for enhanced efficacy.
AuthenticGuaranteeFast DeliveryPrivacy Approval Details and BackgroundArray BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresect···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 72
Approval Details and BackgroundApril 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved B···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 72
Approval Details and BackgroundNEW YORK--(BUSINESS WIRE) October 12, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Admin···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 72
Approval Details and BackgroundNEW YORK--(BUSINESS WIRE) December 20, 2024 -- Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Admi···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 73
Study Publication and BackgroundFRIDAY, May 30, 2025 -- For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overal···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 72
Approval AnnouncementNEW YORK—(BUSINESS WIRE) February 24, 2026 — Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (···【Read More】
Update: 25 Feb,2026Source: Haiou HealthViews: 75
Copyright2024@ BIGBEAR All right reserved BIGBEAR
